Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-loxenatide in patients with mental illness and metabolic disease
ChiCTR2100048253Phase 4Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Aug 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of polyethylene glycol loxenatide in Endocrinopathy, sponsored by Shanghai Ninth People's Hospital. Primary endpoints: uric acid, creatinine and 34 more. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
polyethylene glycol loxenatide
03
Conditions
Endocrinopathy
Beyond the preview
Go deeper on ChiCTR2100048253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048253.